Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access